110 related articles for article (PubMed ID: 20204281)
21. Immunohistochemical analysis of NF-kappaB signaling proteins IKKepsilon, p50/p105, p52/p100 and RelA in prostate cancers.
Seo SI; Song SY; Kang MR; Kim MS; Oh JE; Kim YR; Lee JY; Yoo NJ; Lee SH
APMIS; 2009 Aug; 117(8):623-8. PubMed ID: 19664134
[TBL] [Abstract][Full Text] [Related]
22. Nestin expression is associated with aggressive cutaneous melanoma of the nodular type.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
Mod Pathol; 2014 Mar; 27(3):396-401. PubMed ID: 24030749
[TBL] [Abstract][Full Text] [Related]
23. Bim expression is reduced in human cutaneous melanomas.
Dai DL; Wang Y; Liu M; Martinka M; Li G
J Invest Dermatol; 2008 Feb; 128(2):403-7. PubMed ID: 17637819
[TBL] [Abstract][Full Text] [Related]
24. eIF4E is an adverse prognostic marker of melanoma patient survival by increasing melanoma cell invasion.
Khosravi S; Tam KJ; Ardekani GS; Martinka M; McElwee KJ; Ong CJ
J Invest Dermatol; 2015 May; 135(5):1358-1367. PubMed ID: 25562667
[TBL] [Abstract][Full Text] [Related]
25. Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma.
Maelandsmo GM; Holm R; Nesland JM; Fodstad Ø; Flørenes VA
Clin Cancer Res; 2003 Aug; 9(9):3383-8. PubMed ID: 12960126
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical expression of VEGF, HIF1-a, and PlGF in malignant melanomas and dysplastic nevi.
Konstantina A; Lazaris AC; Ioannidis E; Liossi A; Aroni K
Melanoma Res; 2011 Oct; 21(5):389-94. PubMed ID: 21876459
[TBL] [Abstract][Full Text] [Related]
27. Neuropeptide Y expression in cutaneous melanoma.
Gilaberte Y; Roca MJ; Garcia-Prats MD; Coscojuela C; Arbues MD; Vera-Alvarez JJ
J Am Acad Dermatol; 2012 Jun; 66(6):e201-8. PubMed ID: 21620518
[TBL] [Abstract][Full Text] [Related]
28. NAD(P)H:Quinone Oxidoreductase-1 Expression Sensitizes Malignant Melanoma Cells to the HSP90 Inhibitor 17-AAG.
Kasai S; Arakawa N; Okubo A; Shigeeda W; Yasuhira S; Masuda T; Akasaka T; Shibazaki M; Maesawa C
PLoS One; 2016; 11(4):e0153181. PubMed ID: 27045471
[TBL] [Abstract][Full Text] [Related]
29. NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors.
Lafuente MJ; Casterad X; Trias M; Ascaso C; Molina R; Ballesta A; Zheng S; Wiencke JK; Lafuente A
Carcinogenesis; 2000 Oct; 21(10):1813-9. PubMed ID: 11023538
[TBL] [Abstract][Full Text] [Related]
30. Increased levels of NAD(P)H: quinone oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: A potential biomarker of early damage in the pancreas.
Lyn-Cook BD; Yan-Sanders Y; Moore S; Taylor S; Word B; Hammons GJ
Cell Biol Toxicol; 2006 Mar; 22(2):73-80. PubMed ID: 16532285
[TBL] [Abstract][Full Text] [Related]
31. Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma.
Piras F; Murtas D; Minerba L; Ugalde J; Floris C; Maxia C; Colombari R; Perra MT; Sirigu P
Histopathology; 2007 Jun; 50(7):835-42. PubMed ID: 17543072
[TBL] [Abstract][Full Text] [Related]
32. Impact of E-cadherin expression pattern in melanocytic nevi and cutaneous malignant melanoma.
Seleit IA; Samaka RM; Basha MA; Bakry OA
Anal Quant Cytopathol Histpathol; 2012 Aug; 34(4):204-13. PubMed ID: 23016467
[TBL] [Abstract][Full Text] [Related]
33. The expression of NAD(P)H:quinone oxidoreductase 1 is high in human adipose tissue, reduced by weight loss, and correlates with adiposity, insulin sensitivity, and markers of liver dysfunction.
Palming J; Sjöholm K; Jernås M; Lystig TC; Gummesson A; Romeo S; Lönn L; Lönn M; Carlsson B; Carlsson LM
J Clin Endocrinol Metab; 2007 Jun; 92(6):2346-52. PubMed ID: 17405841
[TBL] [Abstract][Full Text] [Related]
34. A population-based validation of the American Joint Committee on Cancer melanoma staging system.
Gimotty PA; Botbyl J; Soong SJ; Guerry D
J Clin Oncol; 2005 Nov; 23(31):8065-75. PubMed ID: 16258105
[TBL] [Abstract][Full Text] [Related]
35. A NAD(P)H:quinone oxidoreductase 1 polymorphism is a risk factor for human colon cancer.
Begleiter A; Hewitt D; Maksymiuk AW; Ross DA; Bird RP
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2422-6. PubMed ID: 17164365
[TBL] [Abstract][Full Text] [Related]
36. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
[TBL] [Abstract][Full Text] [Related]
37. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase).
Traver RD; Siegel D; Beall HD; Phillips RM; Gibson NW; Franklin WA; Ross D
Br J Cancer; 1997; 75(1):69-75. PubMed ID: 9000600
[TBL] [Abstract][Full Text] [Related]
38. Quinone oxidoreductase 1 is overexpressed in gastric cancer and associated with outcome of adjuvant chemotherapy and survival.
Jiang ZN; Ahmed SMU; Wang QC; Shi HF; Tang XW
World J Gastroenterol; 2021 Jun; 27(22):3085-3096. PubMed ID: 34168410
[TBL] [Abstract][Full Text] [Related]
39. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
de Sá BC; Fugimori ML; Ribeiro Kde C; Duprat Neto JP; Neves RI; Landman G
Melanoma Res; 2009 Jun; 19(3):135-41. PubMed ID: 19369901
[TBL] [Abstract][Full Text] [Related]
40. NADPH:quinone oxidoreductase-1 as a new regulatory enzyme that increases melanin synthesis.
Yamaguchi Y; Hearing VJ; Maeda A; Morita A
J Invest Dermatol; 2010 Mar; 130(3):645-7. PubMed ID: 20145642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
